Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679939 · ClinicalTrials.gov registry record · Phase 4
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
A Phase 4 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT00679939: Completed Phase 4 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.
NCT00679939 is a Phase 4 study of Diabetes Mellitus, Type 2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 226 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679939, a Phase 4 study of Diabetes Mellitus, Type 2, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
Primary Outcome
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Rosiglitazone
Study Locations (20)
California
- GSK Investigational Site - Huntington Park
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Diego
- GSK Investigational Site - Torrance
- GSK Investigational Site - Vista
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
New Mexico
- GSK Investigational Site - Albuquerque
- GSK Investigational Site - Albuquerque
New York
- GSK Investigational Site - East Syracuse
- GSK Investigational Site - Kingston
South Carolina
- GSK Investigational Site - Columbia
- GSK Investigational Site - Columbia
Arizona
- GSK Investigational Site - Tucson
Kentucky
- GSK Investigational Site - Lexington
Louisiana
- GSK Investigational Site - Slidell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2008-04-21 |
| Est. Completion | 2010-09-16 |
| Phase | Phase 4 |
What the finished NCT00679939 record still lists
NCT00679939 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT00679939 names 20 study sites across 11 states, led by California, Florida, New Mexico.
Frequently Asked Questions
What is clinical trial NCT00679939 about?
NCT00679939 is a clinical study titled "Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health". The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
What is the current status of trial NCT00679939?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2008-04-21. Estimated completion is 2010-09-16.
What conditions does trial NCT00679939 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00679939?
The interventions under investigation include: Metformin (DRUG), Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00679939?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679939 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00679939's enrollment target sits among peer trials
226 142nd of 348 higher than 206 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI